ESR1
ESR1geneESR1 hypermethylation associates with coronary heart disease and may alter estrogen-mediated vascular homeostasis and inflammation.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleHypermethylation in CHD; estrogen signaling modulates vascular inflammation.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I41
C — confounder / Type-II72
A — assay feasibility52
E — evidence strength27
T1DI (composite)5
Specificity differential (R−C)-30.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Association between DNA methylation and coronary heart disease or other atherosclerotic events: A systematic review.Atherosclerosis · 2017 · PMID 28577936 · doi